BIO

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Wall Street analysts forecast BIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO is 369.25 USD with a low forecast of 325.00 USD and a high forecast of 437.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bio Rad Laboratories Inc revenue for the last quarter amounts to 653.00M USD, increased 0.50 % YoY.

Bio Rad Laboratories Inc. EPS for the last quarter amounts to -12.70 USD, decreased -154.41 % YoY.

Bio Rad Laboratories Inc (BIO) has 7700 emplpoyees as of December 15 2025.

Today BIO has the market capitalization of 8.31B USD.